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Melissa officinalis L. ethanolic extract inhibits the
growth of a lung cancer cell line by interfering
with the cell cycle and inducing apoptosis
D. B. Magalhães,†a,b,c I. Castro,†b,c,d V. Lopes-Rodrigues,b,c J. M. Pereira,b,c
L. Barros, e I. C. F. R. Ferreira, *e C. P. R. Xavier b,c and M. H. Vasconcelos *a,b,c
Melissa officinalis is a plant from the family Lamiaceae, native in Europe particularly in the Mediterranean
region. Given our interest in identifying extracts and compounds capable of inhibiting tumor cell growth,
and given the antioxidant content and the high consumption of Melissa officinalis in Portugal, this study
aimed to test the tumor cell growth inhibitory activity of five different extracts of this plant (aqueous,
methanolic, ethanolic, hydromethanolic and hydroethanolic) in three human tumor cell lines: MCF-7,
AGS and NCI-H460. All extracts decreased cell growth in all cell lines in a concentration-dependent
manner. The ethanolic extract was the most potent one, presenting a GI50 concentration of approximately
100.9 µg mL−1 in the NCI-H460 lung cancer cells. This extract was characterized by LC-DAD-ESI/MS
regarding its phenolic composition, revealing rosmarinic acid as the most abundant compound. The GI75
concentration of this extract affected the cell cycle profile of these cells. In addition, both the GI50 and
the GI75 concentrations of the extract induced cellular apoptosis. Moreover, treatment of NCI-H460 cells
with this extract caused a decrease in pro-caspase 3 and an increase in p53 levels. This study emphasizes
the relevance of the study of natural products as inhibitors of tumor cell growth.
Introduction
Cancer is a heterogeneous disease caused by genetic altera-
tions in cells. The incidence of cancer is increasing globally,
encouraging the search for new and more effective therapies.
It is known that many of the FDA-approved antitumor drugs
are derived from natural products.1 Therefore, the search for
compounds from natural products with potential antitumor
activity has received increased attention in the last few years.2
Many studies with plant extracts revealed that some of these
plants had anti-tumor activity, thus being a source of com-
pounds for successful development of anticancer drugs.3,4 One
example is paclitaxel (Taxol), derived from Taxus brevifolia
(from the family Taxaceae) and currently clinically used in the
treatment of breast cancer.5,6
Melissa officinalis is one of the most used medicinal plants
in Europe and in the Mediterranean region, where it is known
as lemon balm or, in Portugal, as “erva-cidreira” or just
“cidreira”.7 The leaves of this plant are used to reduce anxiety,
promote sleep and improve symptoms of indigestion.8 Some
studies have also reported antibacterial, antifungal and anti-
inflammatory activities,9 while others have reported antitu-
moral effects for some Melissa officinalis extracts on some
human tumor cell lines.10–12 In order to understand the antitu-
mor activity of this plant, several studies have been conducted
to learn more about its composition. M. officinalis is composed
of polyphenolic compounds such as caffeic acid derivatives
(mostly rosmarinic acid), flavonoids and essential oil. In
addition, it is constituted of glucose (the most abundant
sugar) and vitamins E and C, which have important activity as
inactivators of free radicals.13
The cell growth inhibitory potential of Melissa officinalis
was previously studied in some human tumor cell lines.
However, the cellular mechanism responsible for its cell
growth inhibitory potential has never been studied. Therefore,
the aim of this work was to study the effect of different extracts
of Melissa officinalis (ethanolic, methanolic, hydromethanolic,†These authors equally contributed to this work.
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hydroethanolic and aqueous extracts) on the growth of three
cell lines representative of different types of cancer: the
NCI-H460 cell line from non-small cell lung cancer, the MCF-7
cell line from breast adenocarcinoma and the AGS cell line
from gastric adenocarcinoma. The most potent extract was
further studied in the most sensitive cell line regarding the
effect on cell morphology, cell cycle profile and apoptosis.
Materials and methods
Samples and preparation of Melissa officinalis extracts
Melissa officinalis L. dry leaves were collected in Alfândega da
Fé (Trás-os-Montes, Northeastern Portugal) in February 2016.
Preparation of the infusion extract
The preparation of the infusion extracts was carried out
according to the previously described protocol,14 by extracting
1 g of the dry leaves with 200 mL of boiled water (heating
plate, VELP Scientific) and allowing the extract to stand at
room temperature for 5 minutes. After filtration through
Whatman no. 4 filter paper, the obtained infusions were frozen
and lyophilized.
Preparation of the hydromethanolic, hydroethanolic,
methanolic and alcoholic extracts
To obtain the hydromethanolic, hydroethanolic, methanolic
and ethanolic extracts, 1 g of the dry leaves was extracted twice
with 30 mL of methanol : water and ethanol : water (80 : 20, v/v)
and with 30 mL methanol or ethanol, respectively, in a stirring
plate (at 25 °C and 150 rpm) for 1 hour. After filtration
through Whatman no. 4 filter paper, the final residue of each
extract was then evaporated at 40 °C under reduced pressure,
using a rotary evaporator (Büchi R-210, Flawil, Switzerland).
Stock solutions of all extracts were prepared in 100% sterile
DMSO (methanolic and ethanolic extract) or water (aqueous,
hydromethanolic and hydroethanolic) at a final concentration
of 100 mg mL−1 and further stored at −20 °C.
Cell culture
The three human tumor cell lines used in this study were
MCF-7 (breast adenocarcinoma, from ECACC), NCI-H460 (non-
small cell lung cancer, a kind gift from NCI, Bethesda, MD,
USA) and AGS (gastric adenocarcinoma, from ATCC). These
adherent cell lines were maintained in RPMI-1640 medium
with Ultra-glutamine I (Lonza, Basel, Switzerland) sup-
plemented with heat-inactivated bovine fetal serum (FBS,
Biowest, Riverside, MO, USA). The FBS concentration used was
5% for the cell growth inhibitory assay and 10% for the
remaining assays. Cultures were incubated in the presence of
5% CO2 at 37 °C. Cells were routinely observed with an
inverted microscope (Nikon eclipse TS100 microscope) to
analyse their number and morphology. Passages were made
when confluence reached 80–90% by trypsinization with
TrypLE™ Express (Life Technologies, Carlsbad, CA, USA) and
gentle mechanical detachment. The viable cell number was
regularly determined with the trypan blue (1 : 1) exclusion
assay. All the experiments were performed only when exponen-
tially growing cells presented more than 90% viability.
Phenolic characterization
The phenolic profile was analysed through a LC-DAD-ESI/MS
system (Dionex Ultimate 3000 UPLC, Thermo Scientific, San
Jose, CA, USA). Detection was performed using a diode array
detector (DAD, 280, 330 and 370 nm as preference wave-
lengths) and coupled to a mass spectrometer (Linear Ion Trap
LTQ XL mass spectrometer, Thermo Finnigan, San Jose, CA,
USA), following a procedure previously described by Bessada,
Barreira, Barros, Ferreira & Oliveira (2016).15 Phenolic com-
pound quantification was performed through the calibration
curves of phenolic standards (caffeic acid, ferulic acid, ros-
marinic acid, Sigma-Aldrich, St Louis, MO, USA) and the
results were expressed in mg per g of extract.
Cell growth inhibition assay
The sulforhodamine B (SRB) assay was performed according to
the in vitro anti-cancer drug screening procedure of the
National Center Institute (NCI).16 Cells were plated in 96-well
plates at the previously determined optimal cell concentration.
In the case of MCF-7 and NCI-H460 cells, the appropriate cel-
lular density was 5.0 × 104 cells per well17,18 and for the AGS
cells the cellular density was 7.5 × 104 cells per well.19 Two
plates were prepared, one to be analysed at the time of
addition of the extracts to cells (T0 plate) and the other to be
analysed 48 hours after treating the cells with the extracts.
Cells were incubated for 24 hours to allow cells to adhere to
the plate. In the T48 plate (TPP® Tissue Culture Plates), cells
were then treated with five serial dilutions of each extract,
ranging from 400 µg mL−1 to 25 µg mL−1. Doxorubicin (DOXO)
was used as a positive control, in successive 1 : 2 dilution
ranging from 150 nM to 9.37 nM. The effect of the solvents of
the extracts, DMSO or water, on the growth of the cell lines
was also evaluated (as controls) by treating cells with the
maximum concentration used. After 48 hours of incubation
with the extracts (or immediately for the T0 plate), cells were
fixed by adding ice-cold 10% trichloroacetic acid (TCA, w/v,
Panreac, Barcelona, Spain) and allowed to air-dry. Cells were
then stained with 0.4% sulforhodamine B reagent (SRB, Sigma
Aldrich, St Louis, MO, USA) in 1% (v/v) acetic acid. The bound
dye was then solubilized by adding 10 mM of Tris-base solu-
tion (pH 10.5) (Sigma Aldrich, St Louis, MO, USA). The absor-
bance was measured at 510 nm in a microplate reader
(BioTek® Synergy HT, Winooski, VT, USA). All the SRB experi-
ments used medium supplemented with 5% of FBS (Biowest)
and 1% of antibiotic antimycotic solution (100×, Sigma-
Aldrich, St-Louis, MO, USA). The cell number was determined
as a percentage, compared to untreated cells. The GI50 concen-
tration (concentration that inhibits 50% of net cell growth) was
assessed from the dose–response curves and determined for
each extract and each cell line.
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Preparation of cells for other analysis
For the analysis of the cell cycle, apoptosis or western blot, the
NCI-H460 cells were plated at the density of 1.5 × 105 cells per
well in 6-well plates and incubated for 24 hours. Then, the
cells were treated with Melissa officinalis ethanolic extract at
different concentrations: 100.9 µg mL−1 (approximately the
GI50 concentration) and 180 µg mL
−1 (approximately the GI75
concentration). Blank cells (treated with medium) and control
cells (treated with the same concentrations of DMSO as used
in treatments with the extract: corresponding to the GI50 treat-
ment – control 1 – and corresponding to the GI75 treatment –
control 2) were also included. Cells were then centrifuged at
1200 rpm for 5 minutes at 4 °C. For each treatment, the cell
number and viability were confirmed by the trypan blue exclu-
sion assay (cells were counted using a hemocytometer and
trypan blue reagent; trypan blue penetrates the membrane of
dead cells allowing to distinguish them from the alive ones)
and analyzed in relation to blank cells.
Analysis of the cell cycle profile
Following trypsinization and centrifugation, cells were fixed
with ice-cold 70% ethanol and stored at 4 °C overnight.
Prior to analysis, the cells were centrifuged for 5 minutes at
1200 rpm and re-suspended in PBS containing propidium
iodide (5 µg mL−1; Sigma Aldrich, St Louis, MO, USA) and
RNase A (0.1 mg mL−1; Sigma Aldrich, St Louis, MO, USA).
Samples were kept on ice for at least 30 minutes. Cellular DNA
content was analysed using the flow cytometry (BD Accuri™
C6 Flow cytometry, USA) by analysing at least 20 000 events per
sample.20 The percentage of cells in the G0/G1, S and G2/M
phases of the cell cycle were determined using the FlowJo soft-
ware (version 7.6.0, Tree Star, Inc., Ashland, USA) after cell
debris and aggregate exclusion.
Analysis of apoptosis
For the analysis of apoptosis, after trypsinisation and centrifu-
gation, the pellet of the cells was re-suspended in binding
buffer solution from the Annexin V-FITC Apoptosis Detection
Kit (eBioscience, Bender MedSystems), as indicated by the
manufacturer. The cells were then incubated for 10 minutes
with 5 µL of human Annexin V-FICT and further incubated for
5 minutes with 10 µL of propidium iodide (in the dark and on
ice). Samples were then analysed by flow cytometry using the
BD Accuri™ C6 flow cytometry and respective software, plot-
ting at least 20 000 events per sample.
Analysis of protein expression
Proteins from the different cellular treatments were extracted by
centrifugation of the cells at 1000 rpm for 5 minutes followed
by lysis of the pellet in Winman’s buffer (1% NP-40, 0.1 M Tris-
HCl pH 8.0, 0.15 M NaCl and 5 mM EDTA) with an EDTA-free
protease inhibitor cocktail (Roche, Indianopolis, USA) for
30 minutes at 4 °C (with agitation). The supernatants (corres-
ponding to cellular proteins) were obtained after centrifugation
at 13 000 rpm, at 4 °C for 10 minutes. The total cell protein was
quantified using a modified Lowry assay (Bio-Rad DC Protein
Assay, Hercules, CA, USA).21,22 Bovine serum albumin (BSA,
Sigma Aldrich, St Louis, MO, USA) was used as a protein stan-
dard. After quantification, 20 µg of each cell extract was separ-
ated on 12% Bis-Tris SDS-Page gel at 70 V (for 30 minutes) and
then 100 V (for 1 hour) and transferred to a nitrocellulose mem-
brane (GE Healthcare, Wisconsin, USA) at 100 V (for 1 hour).
Membranes were then blocked in Tris-buffered saline solution
with 0.1% Tween-20 (Promega, Fitchburg, USA) – TBS-T – con-
taining 5% (w/v) of non-fat dry milk, for at least 30 minutes
with agitation at room temperature. Membranes were then incu-
bated with the following primary and secondary antibodies for
1 hour and 30 minutes or 1 hour, respectively, at room tempera-
ture: mouse anti-p53 (Sc-126) (1 : 5000), mouse anti-caspase 3
(sc-7272) (1 : 1000) and goat anti-mouse IgG-HRP (1 : 2000) from
Santa Cruz Biotechnology (Heidelberg, Germany) and mouse
anti-α-tubulin (1 : 10 000) from Sigma Aldrich (St Louis, MO,
USA). The signal from the membranes was detected using the
ECL Western Blot Detection Reagents (GE Healthcare,
Wisconsin, USA), the Amersham Hyperfilm ECL (GE
Healthcare, Wisconsin, USA) and the Kodak GBX developer and
fixer (Sigma Aldrich, St Louis, MO, USA). The intensity of the
bands of each film was analysed using the software Quantity
One – ID Analysis (Bio-Rad), as previously described.23
Statistical analysis
The results of three independent experiments from each etha-
nolic extract were statistically analyzed using the two-tailed
paired Student’s t-test.
Results and discussion
Effect of Melissa officinalis on the growth of several human
tumor cell lines
The different extracts (ethanolic, methanolic, hydromethano-
lic, hydroethanolic and aqueous extracts) of Melissa officinalis
were tested for cell growth inhibitory activity in MCF-7, AGS
and NCI-H460 tumor cell lines, using the sulforhodamine B
(SRB) assay. All the extracts tested presented similar activities
in the three studied cell lines, suggesting that they have a non-
specific effect (Fig. 1). Additionally, it is possible to observe
that higher concentrations of the ethanolic, the hydroethanolic
(only in the NCI-H460 and MCF-7 cells) and the hydrometha-
nolic extracts reduced the cell number to values lower than the
number of cells plated at the beginning of the experiment (i.e.
the T48 plate had fewer cells than the T0 plate), suggesting
that these extracts induce some degree of cell death on these
cell lines (Fig. 1).
The most potent extract was the Melissa officinalis ethanolic
extract and the most potent effect was observed in the NCI-H460
cells, with a GI50 concentration of 100.9 µg mL
−1 (Table 1). On
the other hand, the aqueous extract was the least potent extract
in this study, with values of GI50 always higher than 200
µg mL−1. Saraydin and colleagues tested an aqueous extract of
Melissa officinalis and verified that the extract was very potent,
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with IC50 concentrations of 18 µg mL
−1 in MCF-7 cancer cells.12
The difference between our results and this study may be
explained by the geographic variability of Melissa officinalis –
while the plant used in this work was collected in Portugal, the
plant used in the work of Saraydin et al. was collected in Turkey
– which may influence the natural concentration of the constitu-
ents responsible for the antitumor activity. Indeed, the percen-
tage of the constituents in a plant extract is highly influenced by
exogenous factors such as temperature, climate, soil quality or
the time of the year when the plant is harvested.24 Additionally,
Saraydin et al.measured the IC50 concentration which represents
the concentration that inhibits 50% of a desired activity, while
the GI50 concentration (used in this study) represents the con-
centration that inhibits 50% of cell growth.
Given the obtained GI50 concentrations of the different
Melissa officinalis extracts on the three human tumor cell lines,
the following studies were performed with the most potent
extract (ethanolic extract, EtOH) in the most sensitive cell line
(NCI-H460).
Phenolic characterization of Melissa officinalis
The phenolic profile characteristics of the ethanol extract (final
concentration of 5 mg mL−1) performed by LC-DAD-ESI/MS
Fig. 1 Dose–response curves of different extracts of Melissa officinalis and doxorubicin (as a positive control). Results were determined with the
SRB assay following 48 h treatment of MCF-7, NCI-H460 or AGS cells. The extracts were tested at 5 concentrations ranging from 400 µg mL−1 to
25 µg mL−1. Doxorubicin was tested in successive dilutions ranging from 150 nM to 9.37 nM. Results are presented as percentage (%) of cell growth
when compared to blank (untreated cells). Percentage (%) of growth below zero indicates a decrease in the cell number to values lower than the
ones plated at the beginning of the experiment. Results are the mean ± S.E. of at least 3 independent experiments.
Table 1 GI50 concentrations of different extracts of Melissa officinalis
in three human tumor cell lines
Melissa officinalis extracts




Aqueous 270.0 ± 38.7 260.3 ± 21.6 251.7 ± 27.4
MeOH 151.6 ± 15.3 161.3 ± 2.3 104.0 ± 14.3
EtOH 122.5 ± 9.0 100.9 ± 16.2 108.1 ± 20.6
MeOH·H2O 181.7 ± 18.9 197.0 ± 30.7 166.4 ± 24.5
EtOH·H2O 178.8 ± 28.7 189.6 ± 22.5 204.4 ± 29.5
GI50 refers to the concentration that inhibits 50% of net cell growth.
GI50 concentrations represented in this table correspond to the mean ±
S.E. of at least three independent experiments. Doxorubicin was used
as a positive control: 17.9 ± 14.5 nM in MCF-7 cells, 16.7 ± 1.8 nM in
NCI-H460 cells and 16.7 ± 1.6 nM in AGS cells.
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is shown in Table 2. A total of 20 compounds were identi-
fied taking into account the identification pattern previously
performed by Pereira et al.,25 using an infusion of
M. officinalis. Hydroxycinnamic acid derivatives were the main
class of phenolic compounds present in the extract, specifi-
cally rosmarinic acid (caffeic acid dimer) was the most abun-
dant compound present. The high levels of this compound in
M. officinalis have already been mentioned in the
literature.26,27
Effect of Melissa officinalis on the viability of NCI-H460 cells
The effect of two concentrations (100.9 µg mL−1 – corres-
ponding to the GI50 concentration – and 180 µg mL
−1 – corres-
ponding to the GI75 concentration) of the ethanolic extract of
Melissa officinalis was analysed in terms of cell viability using
the trypan blue exclusion assay. Results (Fig. 2) showed that
the ethanolic extract (EtOH), at either of the concentrations
used, significantly decreased NCI-H460 cell viability.
Treatment with 100.9 µg mL−1 of ethanolic extract reduced cell
viability to approximately 35% while treatment with 180 µg
mL−1 decreased the cell viability to approximately 20% (when
compared to the “blank” cells, Fig. 2G). Neither of the controls
(CTR 50 and CTR 75 of DMSO) had a significant effect on cell
viability in contrast with the treatment with doxorubicin, the
positive control used, which significantly reduced cell viability.
In addition, no significant morphological alterations were
detected on cells treated with the extract when compared to
blank cells (Fig. 2A–F).
Effect of the ethanolic extract of Melissa officinalis on the cell
cycle profile and apoptosis of NCI-H460 cells
In order to understand the effect of the ethanolic extract of
Melissa officinalis on the NCI-H460 cell cycle profile, the
nuclear DNA content of the cells was analyzed by flow cytome-
try following 48 h treatment with the extract. Doxorubicin
treatment was used as a positive control for the assay. Results
demonstrated that in cells treated with the GI50 concentration
of the extract, there were no major alterations in the percen-







ion [M − H]−




1 4.9 279 197 179(995), 135(100) 3-(3,4-Dihydroxyphenyl)-lactic acid1 8.9 ± 0.5
2 5.5 328 311 179(100), 149(93), 135(25) Caftaric acid1 11.4 ± 0.2
3 7.4 324 341 179(100), 149(5), 135(36) Caffeic acid hexoside1 0.36 ± 0.01
4 8.6 326 325 193(100), 149(8), 145(22), 134(40) Fertaric acid2 0.29 ± 0.06
5 11.7 328 179 135(100) Caffeic acid1 2.3 ± 0.1
6 13.3 328 439 359(100), 179(10), 161(38),
135(25)
Sulphated rosmarinic acid3 2.6 ± 0.3
7 13.5 272 571 527(16), 483(65), 439(50), 329(21),
259(25), 241(47), 197(100),
179(72), 135(85)
Yunnaneic acid E3 7.5 ± 0.5
8 14.7 275, 322sh 537 493(55), 359(10), 313(25), 295
(100), 269(25), 197(15), 179(72),
135(40)
Lithospermic acid A isomer3 90 ± 2
9 15.5 328 473 311(15), 293(16), 179(66),
149(100), 135(30)
Chicoric acid1 4.5 ± 0.3
10 17.4 273, 332sh 597 359(30), 295(25), 197(12), 179(11),
135(10)
Yunnaneic acid F3 6.2 ± 0.1
11 18.6 265, 335sh 553 491(8), 359(3), 311(5), 197(3),
179(18), 161(10), 135(100)
Salvianolic acid C derivative I3 11.5 ± 0.4
12 18.9 264, 335sh 553 491(10), 359(3), 311(5), 197(3),
179(18), 161(11), 135(100)
Salvianolic acid C derivative II3 4.7 ± 0.3
13 19.7 326 521 359(100), 197(19), 179(27),
161(68), 135(19)
Rosmarinic acid hexoside3 14.3 ± 0.7
14 21.8 284, 328sh 719 539(18), 521(14), 359(100),
197(21), 179(24), 161(89), 135(8)
Sagerinic acid3 13.5 ± 0.8
15 24.7 328 359 197(79), 179(68), 161(100),
135(21)
Rosmarinic acid3 184.4 ± 0.3
16 27.9 326 493 359(72), 313(5), 295(50), 269(5),
197(30), 179(40)
Salvianolic acid A3 25.9 ± 0.8
17 28.9 328 829 667(89), 535(100), 491(20),
311(35), 293(10), 179(8)
Salvianolic acid C derivative III3 20 ± 1
18 30.7 288, 326sh 537 493(50), 359(100), 313(5), 295(16),
269(3), 197(38), 179(55)
Lithospermic acid A3 60 ± 2
19 31.4 322 493 359(100), 313(5), 295(5), 269(5),
197(13), 179(39)
Salvianolic acid A isomer3 4.8 ± 0.9
20 35.1 288, 322sh 715 535(100), 491(34), 311(63), 293(5),
179(5), 135(18)
Salvianolic acid C derivative IV3 6.9 ± 0.2
Total phenolic compounds 480 ± 5
Phenolic compound standards used for the quantification: 1 – caffeic acid, 2 – ferulic acid and 3 – rosmarinic acid.
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tage of cells in the different phases of the cell cycle. However,
in cells treated with the GI75 concentration of the ethanolic
extract of Melissa officinalis there was a statistically significant
decrease in the % of cells in the G2/M phase of the cell cycle
(Fig. 3).
In order to verify whether the extract has an effect on cellu-
lar apoptosis, the Annexin V-FITC/PI assay was performed by
flow cytometry. The ethanolic extract of Melissa officinalis
induced apoptosis on NCI-H460 cells in both tested concen-
trations when compared with blank and the respective controls
(CTR 50 and CTR 75). When the cells were treated with the
GI50 concentration of this extract, the % of cells undergoing
apoptosis increases from 4.1% in blank cells to 19.1%. When
the cells were treated with the GI75 concentration of the extract
they presented 28.3% of cells in apoptosis (Table 3). These
results show that the ethanolic extract of Melissa officinalis has
a potent and dose-dependent effect on cellular apoptosis in
NCI-H460 cells.
Other studies have previously shown the apoptotic activity
of other types of Melissa officinalis extracts in human breast
cancer cells.12 Nevertheless, the effect of the ethanolic extract
of this plant on the apoptosis of NCI-H460 cells has, to our
knowledge, never been previously reported.
Fig. 2 Representative photographs of NCI-H460 human tumor cells treated for 48 h with the ethanolic extract of Melissa officinalis or with a posi-
tive control (doxorubicin). (A) Blank; (B) positive control – doxorubicin; (C) control of the GI50 concentration of the extract; (D) treatment with the
GI50 concentration of the extract; (E) control of the GI75 concentration of the extract and (F) treatment with the GI75 concentrations of the extract.
The graph (G) represents the effect of Melissa officinalis ethanolic extract on NCI-H460 cellular viability following 48 h of treatment, determined
with the trypan blue exclusion assay. The % of viable cells was calculated in relation to blank. Conditions tested were: complete medium (blank);
GI50 and GI75 concentrations of the ethanolic extract (EtOH) and the solvent (DMSO) concentration corresponding to the one used in each extract
concentration (CTR 50 and CTR 75). Doxorubicin (DOXO) 17 nM was used as a positive control. Results are the mean ± S.E. of three independent
experiments. * indicates p ≤ 0.05 between the extract treatment and blank.
Fig. 3 Effect of Melissa officinalis ethanolic extract on the NCI-H460
cell cycle profile. Cells were treated for 48 h with complete medium
(blank); with the extract at a concentration that inhibited cell growth by
50% (GI50, 100.9 µg mL
−1) or 75% (GI75, 180.0 µg mL
−1) or with DMSO at
concentrations corresponding to the extract GI50 (CTR 50) or GI75 (CTR
75). Cells were also treated with 17 nM of doxorubicin (DOXO), used as a
positive control. Results are the mean ± S.E. of three independent
experiments. * indicates p ≤ 0.05 between the extract treatment and
blank.
Table 3 Apoptosis levels of NCI-H460 cells treated with Melissa offici-
nalis ethanolic extract
Conditionsa % Apoptosis
Blank 4.1 ± 1.1
CTR 50 4.1 ± 1.5
CTR 75 6.7 ± 3.8
GI50 19.1 ± 4.0
GI75 28.3 ± 6.5
DOXO 44.7 ± 6.4
a Cells were treated for 48 h with complete medium (blank); with the
GI50 and GI75 concentrations of the extract or with DMSO at concen-
trations corresponding to the extract GI50 (CTR 50) and GI75 (CTR 75).
Doxorubicin (DOXO) at 17 nM was used as a positive control. Results
are represented as the mean ± S.E. of three independent experiments.
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The effect of the ethanolic extract on the expression levels
of proteins involved in the cell cycle and apoptosis was also
assessed. Results obtained from the western blot analysis
showed a significant increase in the levels of p53 expression in
treatments with the GI50 and GI75 concentrations of the
extract, when compared with the blank and the controls
(Fig. 4). This is in agreement with the results obtained in the
cell cycle and apoptosis analysis, since it is known that an
increase in the levels of p53 expression may be responsible for
alterations in the cell cycle and an increase in apoptotic
levels.28–31 In addition, the GI50 concentration of the ethanolic
extract of Melissa officinalis decreased the expression levels of
pro-caspase 3 when compared with the blank and the control
cells. This is in agreement with the results obtained with the
Annexin assay, since a reduction of pro-caspase 3 levels is
indicative of the activation of caspase cleavage in the late
stages of apoptosis.32–34 Unfortunately, when treating cells
with the GI75 concentration of this extract, it was not possible
to properly analyze the expression of these proteins since the
obtained results varied substantially between experiments
(high error bars of Fig. 4B), probably due to the high levels of
apoptosis in the cells treated with the extract. Nevertheless, the
results obtained with the GI50 treatment further confirmed
that the ethanolic extract of Melissa officinalis induces apopto-
sis in NCI-H460 cells.
Conclusions
Previous studies have investigated the antitumor effects of the
aqueous, ethanolic and hydroalcoholic extracts of Melissa
officinalis. Nevertheless, the mechanism of action of such
extracts was never previously investigated. The results here
obtained revealed that the ethanolic extract presented the
highest cell growth inhibitory potential in all the human
tumor cell lines tested. The most sensitive cells to this extract
treatment were the non-small cell lung cancer cells
(NCI-H460). Furthermore, results showed that this extract
affects the cell cycle profile of NCI-H460 cells and induces cell
death by apoptosis. This study highlights the importance of
studying the ethanolic extract of Melissa officinalis as a source
of bioactive compounds with antitumor activity.
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